2026 · Poster Presentation · Keith Knapp · Dermatology
29
Total Publications
9
Abstract/Manuscript
2
Oral Presentation
18
Poster Presentation
2025 · Poster Presentation · Pharma Partner · Dermatology
Correlation between achieving SALT 20 score and clinician- and patient-reported outcomes among patients diagnosed with alopecia areata in the US: An assessment from the TARGET-DERM AA registry.
Read more →2025 · Poster Presentation · Northwestern University · Dermatology
Race and ethnicity sub-groups of alopecia areata patients have differing clinical characteristics: TARGET-DERM AA.
Read more →2025 · Poster Presentation · Pharma Partner · Dermatology
Generic vs. disease-specific patient reported outcome (PRO) instruments for assessing HRQoL burden among patients diagnosed with alopecia areata: Evidence from TARGET-DERM AA.
Read more →2025 · Poster Presentation · Yes · Methods/Pharmacoepi
Power Vs. Precision When Estimating Risk Differences Using Observational Data? A Case Study From TARGET-IBD.
Read more →2025 · Abstract/Manuscript · Atopic Dermatitis (AD)
Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry.
Read more →2024 · Poster Presentation · Medical University of South Carolina · Dermatology
Demographics and disease characteristics of patients with alopecia areata with comorbid atopic dermatitis, vitiligo or anxiety/depression: TARGET-DERM AA.
Read more →2024 · Poster Presentation · Atopic Dermatitis (AD) · Dermatology
Why Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from the TARGET-DERM AD Registry.
Read more →2024 · Poster Presentation · Keith Knapp · Dermatology
Real-world study of hidradenitis suppurativa: skin lesions and pain are associated with Hurley Stage in TARGET-DERM HS.
Read more →2024 · Poster Presentation · Derek Gazis · Gastroenterology
Predictors of Patients Receiving No Medication for Treatment of Eosinophilic Esophagitis in the United States: Data from the TARGET-EGIDS Cohort.
Read more →2024 · Poster Presentation · Keith Knapp · Gastroenterology
Time to Diagnosis Among Patients with Eosinophilic Esophagitis in the United States.
Read more →2024 · Oral Presentation · Keith Knapp · Dermatology
Patient reported burden is associated with clinician-reported severity in alopecia areata: Real world insights from TARGET-DERM AA.
Read more →2023 · Poster Presentation · Derek Gazis · Gastroenterology
Outcomes of early vs. delayed advanced therapy among patients with moderate ulcerative colitis in the United States: TARGET-IBD.
Read more →2023 · Poster Presentation · Derek Gazis · Gastroenterology
Treatment Journey among patients with moderate ulcerative colitis in the United States: TARGET-IBD.
Read more →2023 · Abstract/Manuscript · Atopic Dermatitis (AD)
Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort.
Read more →2023 · Abstract/Manuscript · Atopic Dermatitis (AD)
Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry.
Read more →2023 · Abstract/Manuscript · Yes
Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease.
Read more →2023 · Abstract/Manuscript · Yes
Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation.
Read more →2022 · Poster Presentation · Pharma Partner · Gastroenterology
Treatment patterns among moderate-to-severe ulcerative colitis patients in TARGET-IBD.
Read more →2022 · Poster Presentation · Yes · Gastroenterology
Inflammation on Index Biopsy Predicts Loss of Remission Among Ulcerative Colitis Patients with Endoscopic Remission: a US Cohort Analysis.
Read more →2022 · Poster Presentation · Yes · Methods/Pharmacoepi
Healthcare Utilization and Charges Associated with US Hospitalized Adult Patients with COVID 19.
Read more →2022 · Abstract/Manuscript · Atopic Dermatitis (AD)
Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort.
Read more →2021 · Poster Presentation · Yes · Gastroenterology
Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort.
Read more →2021 · Abstract/Manuscript · Yes
Methodology and initial results from a real-world observational cohort of patients with inflammatory bowel disease: TARGET-IBD.
Read more →2021 · Abstract/Manuscript · Yes
Factors Associated with Readmission in the US Following Hospitalization with COVID-19.
Read more →2020 · Poster Presentation · Pharma Partner · Gastroenterology
Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD.
Read more →2020 · Abstract/Manuscript · Yes
Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States.
Read more →2020 · Oral Presentation · Yes · Gastroenterology
Objective Disease Activity Assessment and Therapeutic Drug Monitoring is Lacking Prior to Biologic Therapy Changes in Routine Inflammatory Bowel Disease Clinical Practice: TARGET-IBD.
Read more →2019 · Poster Presentation · Yes · Methods/Pharmacoepi